Declining estrogen and androgen levels can disrupt lacrimal and meibomian gland function, driving evaporative dry eye during ...
Yehia Hashad, MD, discusses BL1332's phase 1b pain data and what's ahead as the TRPV1 antagonist enters phase 2 in patients ...
Cataract safety, Glaucoma drugs and MIGS, plus Artificial Intelligence debates and retina breakthroughs—key FDA moves and trial updates in ophthalmology. Retina specialists weighed in on the FDA's ...
Jordi Mones, MD, PhD, discusses what is believed to be the first direct-to-phase 2 trial testing an optogenetic gene therapy to restore vision lost to GA.
Cerebral visual impairment is now the leading cause of childhood vision loss. Three experts explain the history, science, and clinical signs eye care providers need to know.
Cerebral visual impairment is now the leading cause of childhood vision loss. Three experts explain the history, science, and clinical signs eye care providers need to know.
A same-platform, prospective comparison of 123 eyes suggests diffractive trifocal optics don't compromise standard automated perimetry outside the central 5° Cataract remains the leading cause of ...
Retina specialist David A. Eichenbaum, MD, FASRS, discusses KSI-101 (tabirafusp alfa), a dual IL-6/VEGF-blocking biologic in the Phase 3 PEAK trial, as a potential steroid-sparing, first-line therapy ...
A priority review in Stargardt disease, two pivotal-trial milestones, an emerging bispecific for wet AMD, and new diagnostic ...
Antibiotic injection reduced endophthalmitis risk vs topical drops after cataract surgery, meta-analysis found.
Cerebral visual impairment is now the leading cause of childhood vision loss. Three experts explain the history, science, and clinical signs eye care providers need to know.
Jonathan Gloth, MD, discusses how a dual Tie2/VEGF mechanism could reduce injection burden and the consequences of missed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results